Related Experiment Videos
[Progress in adjuvant therapy for colorectal cancer]
Shunji Kohnoe1, Yoshihiro Kakeji, Yoshihiko Maehara
1Department of Gastroenterological Surgery, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 1, 2003
Summary
Adjuvant chemotherapy with 5-FU/leucovorin is standard for resectable colon cancer. Oral 5-FU prodrugs may soon replace infusion, while rectal cancer adjuvant therapy focuses on chemotherapy due to surgical factors.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Context:
- Review of adjuvant therapy for resectable colorectal cancers.
- Current standard for Dukes'C colon cancer is 5-FU/leucovorin chemotherapy.
- Controversy exists regarding adjuvant chemotherapy for Dukes'B colon cancer.
Purpose:
- To review the progress and role of adjuvant therapy in resectable colorectal cancers.
- To discuss the evolving landscape of chemotherapy agents.
- To compare adjuvant therapies for colon and rectal cancers.
Summary:
- 5-FU/leucovorin is the standard adjuvant chemotherapy for Dukes'C colon cancer.
- Oral 5-FU prodrugs (UFT, capecitabine) are poised to replace 5-FU infusion.
- Radiation therapy for rectal cancer reduces local recurrence but not survival; chemotherapy is preferred in Japan, with surgery being key.
- Local recurrence in rectal cancer is linked to surgical technique and surgeon skill.
Impact:
- Highlights the shift towards oral chemotherapy agents for colon cancer.
- Underscores the importance of surgical expertise in managing rectal cancer.
- Provides insights into regional differences in adjuvant treatment strategies for colorectal cancer.